Polycystic Ovary Syndrome has Risk of Nonalcoholic Fatty Liver Disease (NAFLD)
Mar 2, 2005 - 6:01:00 PM
The research findings are important because many ob/gyn physicians are not aware that NAFLD can be a problem for these patients. As a result, they do not screen for the disease and may treat PCOS patients with medications that can potentially cause toxicity to the liver if they have NAFLD.
By LA BioMed, [RxPG] According to new research by a group of Southern California researchers, women with polycystic ovary syndrome (PCOS) are at increased risk for developing nonalcoholic fatty liver disease (NAFLD). PCOS is a hormone imbalance manifested by insulin resistance that interferes with normal ovulation and fertility.
The research findings are important because many ob/gyn physicians are not aware that NAFLD can be a problem for these patients. As a result, they do not screen for the disease and may treat PCOS patients with medications that can potentially cause toxicity to the liver if they have NAFLD.
The researchers noted that NAFLD represents a spectrum of liver diseases that can be mild in many patients but is also recognized as an important cause of cirrhosis, liver transplantation, and liver cancer. They recommended that patients with PCOS be evaluated for liver disease and those with elevated ALT avoid alcohol and acetaminophen. Liver disease is often silent and often isn't discovered until it reaches advanced levels.
The impetus for the study began with two observations: liver specialists have seen a large increase of fatty liver disease, which has been linked to insulin resistance; PCOS has also been linked to insulin resistance. The study noted that PCOS is the most common form of non-ovulating infertility and females are at a higher risk than men for the extreme manifestations of fatty liver disease such as cirrhosis and liver carcinoma.
Publication:
The team's results were published in the February issue of Fertility and Sterility and is the first paper to show the association between PCOS and NAFLD.
On the web:http://www.rei.edu/
Advertise in this space for $10 per month.
Contact us today.
Omid Khorran M.D., Ph.D. a principal investigator at LA BioMed and Director, Division of Reproductive Endocrinology and Fertility at Harbor-UCLA Medical Center, was part of the research group who conducted the study.
Feedback
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
